Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780970 | 0.79 | — | — | |
| SCHEMBL18920437 | 0.77 | KDM4E (0.41) | — | |
| SCHEMBL19643296 | 0.76 | OPRL1 (0.37) | OPRL1MAPK1 | |
| Hydrochloric Acid SCHEMBL30639439 | 0.74 | MAOA (0.40) | OPRL1MAPK1 | |
| SCHEMBL18919951 | 0.72 | LMNA (0.32) | — | |
| SCHEMBL239640 | 0.72 | — | — | |
| SCHEMBL18919960 | 0.71 | NPC1 (0.31) | — | |
| SCHEMBL18920209 | 0.71 | EPHX2 (0.33) | — | |
| SCHEMBL3259397 | 0.68 | — | — | |
| SCHEMBL20994264 | 0.68 | OPRL1 (0.37) | OPRL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3383866-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093938-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093938-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | MAVS, EIF2AK2, SARS1 | OPRL1 1207/4885MAPK1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.